Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia.

Content Provider	Europe PMC
Author	M'harzi, Soulaimane Elouali, Aziza Lahrache, Karim Ghanam, Ayad Babakhouya, Abdeladim Rkain, Maria Benajiba, Noufissa
Copyright Year	2022
Abstract	Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children,representing 25–30% of all childhood malignancies. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients who experience severe adverse events. L-Asparaginase is an effective antineoplastic agent used in chemotherapy of ALL. Despite its indisputable indication, it can cause various adverse effects, including acute pancreatitis (AP). Recently, an increase in the number of pediatric AP cases following L-Asparaginase in Acute Lymphoblastic Leukemia been reported. We presented a case of acute pancreatitis in children with ALL induced by administration of L-ASPA preparations.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9668613&blobtype=pdf
Journal	Leukemia Research Reports [Leuk Res Rep]
Volume Number	18
DOI	10.1016/j.lrr.2022.100357
PubMed Central reference number	PMC9668613
PubMed reference number	36405565
e-ISSN	22130489
Language	English
Publisher	Elsevier
Publisher Date	2022-11-09
Access Restriction	Open
Rights License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2022 The Author(s). Published by Elsevier Ltd.
Subject Keyword	Acute pancreatitis L-asparaginase ALL
Content Type	Text
Resource Type	Article
Subject	Hematology Oncology